

## **A Primary Care Approach to the Diagnosis and Management of Peripheral Arterial Disease**

David L. Dawson, MD, FACS

Associate Professor, Uniformed Services University of the Health Sciences

### **Objectives:**

- Be able to recognize characteristic symptoms of intermittent claudication
- Diagnose PAD on the basis of history, physical exam, and simple limb blood pressure measurements
- Recognize the significance of peripheral artery disease as a marker for coronary or cerebrovascular atherosclerosis
- Provide appropriate medical management of atherosclerosis risk factors—including use of antiplatelet therapy to reduce risk of myocardial infarction, stroke and death
- Manage symptoms of intermittent claudication with program of smoking cessation, exercise, and medication

The diagnosis of intermittent claudication secondary to peripheral artery disease (PAD) can often be made on the basis of history and physical examination. Additional evaluation of PAD is multi-modal and the techniques used will vary depending on the nature and severity of the patient's presenting problem. Most patients can be appropriately managed without referral for specialized diagnostic services or interventions.

### **Claudication**

The incidence and prevalence of PAD increases with age. Claudication is the most common symptom of lower extremity PAD with an estimated prevalence of >350,000 in the US. About only 5% of patients with claudication will ever develop critical (limb threatening) ischemia.

Claudication is pain, aching or muscle fatigue occurring after the onset of exercise (walking) and relieved by rest. The history is characteristic and reproducible, and the history alone is enough for diagnosis in most cases. A complete physical examination is indicated, however, to evaluate potentially important contributing factors that may impact clinical management. Pulse palpation should be correlated with symptom severity and location. Auscultation of bruits may be helpful, as well.

Claudication is a marker for atherosclerotic cardiovascular disease. The 20-25% five-year mortality of patients with claudication is significantly higher than comparable populations without claudication. Patients with claudication frequently have significant coronary or cerebrovascular disease, with a correlative incidence of myocardial infarction or stroke. Patients with claudication should be evaluated for risk factors for atherosclerosis, including hypertension, lipid abnormalities, and diabetes mellitus. The following blood tests should be performed in all new patients presenting with PAD:

- Complete blood count
- Platelet count
- Fasting blood glucose or hemoglobin A<sub>1c</sub>
- Creatinine
- Fasting lipid profile
- Urinalysis (for glycosuria/proteinuria)

In addition, for patients with and early age of onset, personal or family history of thrombotic events, or a lack of common risk factors for atherosclerosis, the following laboratory investigations are indicated:

- Hypercoagulability screen
- Homocysteine levels



Unless contraindicated, patients with atherosclerotic disease should be on aspirin, or other antiplatelet therapy. Management guidelines for PAD patients are summarized in the accompanying table.

### **Ankle/Brachial Index**

Objective findings can help confirm the diagnosis of hemodynamically significant peripheral artery disease. Because of its simplicity, the ankle brachial index (measured with continuous wave Doppler and pneumatic cuffs) remains a mainstay of screening for PAD. The ankle/brachial index (ABI) is defined as:

$$\text{Ankle/Brachial Index (ABI)} = \frac{\text{ankle pressure (higher of the tibial artery pressures)}}{\text{brachial pressure (higher of the two arm pressures)}}$$

The ABI should be measured in both legs of all new patients with intermittent claudication. The ABI is considered abnormal if it is  $\leq 0.90$ , but a normal individual will typically have an ABI of 1.0 to 1.10. (Though the normal mean blood pressure at the ankle is equal to mean brachial pressure, the pressure waveforms are different. The normal ankle systolic blood pressure—measured with the patient supine—is slightly higher than the brachial artery systolic pressure.) Patients with moderately severe intermittent claudication typically have an ABI in the range of 0.70 to 0.90. The lower the ABI, the more severe the disease. Patients with critical ischemia often have an ABI  $< 0.35$ .

### **Treadmill Exercise Testing**

Treadmill testing is sometimes useful in the evaluation of patients with claudication. Treadmill tests can be conducted in a variety of ways, but usually the speed is kept constant, for example, 2 mi/h (3.2 km/h). Either a fixed incline can be used, or a graded intensity test profile can be selected.

The time or distance walked until the onset of claudication symptoms should be recorded. This is the "pain free walking distance" (PFD) or the "initial claudication distance" (ICD). When claudication symptoms stop the patient from walking any farther, the patient has reached the "maximum walking distance" (MWD) or "absolute claudication distance" (ICD). Pain is subjective and results for some patients may be markedly different from others with similar severity of occlusive disease. Also, a variability of  $\pm 20\%$  is not uncommon if the tests are repeated for a single patient on different days.

Treadmill walking distances can be compared before and after therapy to evaluate the efficacy of the intervention.

Treadmill walking tests are also useful for objectively documenting the severity of, or confirming a diagnosis of claudication. A post-exercise drop in the ankle pressure of  $\geq 20$  mm Hg is to be expected when patient's symptoms are truly from vasculogenic claudication. A greater pressure drop, and a longer recovery time, indicates more severe disease.

Some patients may have both mild to moderate PAD and musculoskeletal or neurospinal conditions. If they develop symptoms that stop their walking early, but they do not have an associated drop in ankle pressure; it is unlikely that vascular disease is the exercise-limiting condition.

Treadmill tests can also be useful to document mild to moderate proximal occlusive disease that only becomes hemodynamically significant under conditions of exercise. Some patients with aortoiliac disease may have intact pulses and near normal resting segmental pressures. However, after exercising on the treadmill a drop in the limb pressures will be detectable.



## **Peripheral Arterial Duplex Scanning**

If it is desirable to localize and gauge the severity of the PAD in order to assist with the planning of an intervention, duplex scanning or magnetic resonance arteriography can be used as a preliminary, noninvasive examination before arteriography. Arteriography is only indicated when a decision has already been made to intervene, should a suitable lesion or pattern of disease be identified.

An experienced vascular sonographer can image the lower extremity arterial tree from the diaphragm to the feet. While some studies can be limited by abnormal or distorted anatomy (obesity, bowel gas, open wounds, etc.), most patients can be successfully studied with ultrasound. Complete arterial mapping can take two hours or more, though. Ultrasound B-mode imaging reliably demonstrates aneurysms, pseudoaneurysms, and other morphologic features. Color flow imaging facilitates vessel identification (especially useful when scanning small or deeply situated vessels). Color flow imaging and pulsed Doppler can demonstrate patency, focal stenosis, and can characterize segmental hemodynamics, but overall accuracy is better for larger, proximal segments.<sup>1</sup> Further, the ability to specifically characterize degree of arterial narrowing with duplex scanning is limited when there is significant proximal disease and when the segment of interest has diffuse, rather than focal narrowing. Severe stenoses are generally characterized by focal increases in velocity, but this may not be seen if the stenosis is not well localized.

## **Office-based management of PAD**

Claudication can significantly effect the quality of life of affected individuals. The first line of therapy is a program of regular exercise and smoking cessation. Pharmacologic treatment options include pentoxifylline (Trental®) or cilostazol

(Pletal®), but in a prospective, blinded comparison trial, cilostazol improved walking ability more than either pentoxifylline or placebo. For patients with lifestyle limiting symptoms that are not adequately managed with these means, surgical or endovascular revascularization could be considered.

**Additional Reading:**

Dormandy J, Rutherford R. Management of peripheral arterial disease (PAD). TASC Working Group. *J Vasc Surg.* 2000;31:S1-S296.



## Medical Management Guidelines for Peripheral Arterial Disease (PAD) Patients\*

Goals	Therapy	Comments
Antiplatelet therapy	Aspirin (ASA)  Clopidogrel (Plavix®)	↓ risk of MI <sup>†</sup> , stroke, vascular death <sup>2, 3</sup>  ASA may reduce need for surgery for PAD <sup>4</sup>  Clopidogrel may be more effective for risk reduction for PAD patients <sup>5</sup>
<b>Management of specific atherosclerosis risk factors:</b>		
Cigarette smoking	Behavioral programs  Nicotine replacement  Bupropion (Wellbutrin®)	↓ risk of PAD progression, MI, stroke, death <sup>6, 7</sup>  ↓ risk of critical ischemia and limb loss <sup>8</sup>
Obesity	Dietary modification  ↑physical activity	
Diabetes mellitus	Dietary therapy  Oral hypoglycemics; Metformin (Glucophage®) and others  Insulin	Intensive glycemic control may improve outcomes, including ↓ risk of MI and death <sup>9-11</sup>  Recommend fasting blood glucose 80 to 120 mg/dL; postprandial glucose <180 mg/dL; hemoglobin A <sub>1c</sub> <7.0%

\* Adapted from the recommendations of the TransAtlantic Inter-society Consensus<sup>1</sup>

<sup>†</sup> MI: myocardial infarction

Hyperlipidemia	<p>Screen all PAD patients</p> <p>Dietary modification</p> <p>Medications if LDL-cholesterol <math>\geq 100</math> mg/dL</p> <p>Consider niacin for low HDL-cholesterol</p> <p>Consider fibrates for low HDL-cholesterol and high triglycerides</p>	<p>Lp(a) in an independent risk factor for PAD<sup>12</sup></p> <p>PAD may stabilize or regress with therapy<sup>13-17</sup></p> <p>↓ risk of PAD progression<sup>18</sup></p> <p>↓ risk of MI and cardiovascular death<sup>19-21</sup></p>
Hypertension	<p>Manage according to guidelines from Joint National Committee (VI), National Heart, Lung, and Blood Institute</p>	<p>Correlation to PAD progression not established</p> <p>Marked ↓ in systolic pressure may slightly worsen claudication symptoms<sup>22</sup></p> <p>No contraindication to <math>\beta</math>-blocker use<sup>23</sup></p> <p>ACE<sup>†</sup> inhibitor (ramipril, Altace®) may ↓ risk of MI or death in PAD patients<sup>24</sup></p>
Hypercoagulable states	Warfarin (Coumadin®)	
Hyperhomocysteinemia	<p>Folic acid</p> <p>Vitamin B12</p> <p>Vitamin B6</p>	<p>Elevated plasma homocysteine is important PAD risk factor in patients &lt;50 years<sup>25</sup></p> <p>Treatment ↓ risks of cardiovascular events and death<sup>26, 27</sup></p>
Post-menopausal state	Hormone replacement therapy (estrogen and progesterone)	<p>May ↓ risk of cardiovascular events in women<sup>28</sup></p>

<sup>†</sup> ACE: angiotensin converting enzyme



## References for Table

1. Dormandy J, Rutherford R. Management of peripheral arterial disease (PAD). TASC Working Group. *J Vasc Surg.* 2000;31:S1-S296.
2. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. *Br Med J (Clin Res Ed).* 1998;296:320-331.
3. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. *J Intern Med.* 1990;227:301-308.
4. Goldhaber S, Manson J, Stampfer M, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. *Lancet.* 1992;340:143-145.
5. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet.* 1996;348:1329-1339.
6. Juergens J, Barker N, Hines E. Arteriosclerosis obliterans: A review of 520 cases with special reference to pathogenic and prognostic factors. *Circulation.* 1960;21:188-195.
7. Smith I, Franks P, Greenhalgh R, Poulter N, Powell J. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischemia. *Eur J Vasc Endovasc Surg.* 1996;11:402-408.
8. Hirsch A, Treat-Jacobson D, Lando HA, Hatsukami D. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. *Vasc Med.* 1997;2:243-251.
9. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group. *JAMA.* 1996;276:1409-1415.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet.* 1998;352:837-853.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS). *Lancet.* 1998;352:854-865.



12. Valentine R, Grayburn P, Vega G, Grundy S. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. *Arch Intern Med.* 1994;154:801-806.
13. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA.* 1984;251:351-364.
14. Duffield R, Lewis B, Miller N, Jamieson C, Brunt JN, Cochester A. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis; a randomised controlled trial. *Lancet.* 1983;2:639-642.
15. Blankenhorn D, Azen S, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. *Circulation.* 1991;83:438-447.
16. de Groot E, Jukema J, van Boven A, et al. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. *Am J Cardiol.* 1995;76:40C-46C.
17. Olsson A, Ruhn G, Erikson U. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study. *J Intern Med.* 1990;227:381-390.
18. Pedersen T, Kjekshus J, Pyörälä K, Olsson A, Musliner T, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). *Am J Cardiol.* 1998;81.
19. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *JAMA.* 1993;269:3015-3023.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994;344:1383-1389.
21. Freemantle N, Barbour R, Johnson R, Marchment M, Kennedy A. The use of statins: a case of misleading priorities? *BMJ.* 1997;315:826-828.
22. Solomon S, Ramsay L, Yeo W, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. *BMJ.* 1991;303:1100-1104.
23. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. *Arch Intern Med.* 1991;151:1769-1776.
24. Yusuf S, Sleight P, Pogue J, Bosch J, Davies J, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in



high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000;342:145-153.

25. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. *N Engl J Med*. 1991;324:1149-1155.
26. Boushey C, Beresford S, Omenn G, Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA*. 1995;274:1049-1057.
27. Nygard O, Nordrehaug J, Refsum H, Ueland P, Farstad M, Vollset S. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med*. 1997;337:230-236.
28. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA*. 1998;280:605-613.

## **Pharmacotherapy for Symptoms of Intermittent Claudication<sup>§</sup>**

### **FDA<sup>®</sup>-approved drugs (recommended options)**

Cilostazol

Pentoxifylline

### **Other established drugs with some or potential benefit for claudication**

Buflomedil

Naftidrofuryl

### **Therapies with minimal or no benefit (not recommended for clinical use)**

Antiplatelet drugs

Aminophylline

Anticoagulation

Cinnarizine

Defibrotide

Dextran

Ginkgo biloba

Isosuprine

Isovolemic hemodilution

Ketanserin

Nicotinic acid derivatives

Vasodilators

Verapamil (and other calcium channel blockers)

Vitamin E

### **Incompletely studied drugs with potential benefit (not yet FDA-approved)**

Beraprost sodium

Carnitine

L-arginine

Propionyl-L-carnitine

Prostaglandins and prostanoids

Protein kinase C inhibitors

Vascular endothelial growth factor (VEGF)

---

<sup>§</sup> Adapted from recommendations of the TransAtlantic Inter-Society Consensus, reported by Dormandy J, Rutherford R. Management of peripheral arterial disease (PAD). TASC Working Group. *J Vasc Surg.* 2000;31:S1-S296.



---

\*\* FDA: United States Food and Drug Administration

# Treatment Algorithm for Patients with Peripheral Artery Disease

